Johannes Waiser

Charité - Universitätsmedizin Berlin

Papers

1

Total Citations

23

H-Index

1

About

Johannes Waiser is a leading clinical researcher whose work centers on the intersection of radiation oncology and nephrology, with a particular focus on noninvasive treatments for renal cell carcinoma (RCC). His major contribution lies in pioneering the application of robotic stereotactic ablative radiotherapy (SABR) for patients with RCC who have impaired renal function—a population often excluded from standard surgical or ablative therapies. His most cited paper, "Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function" (2019, 23 citations), demonstrates that SABR can deliver high, tumoricidal doses while preserving healthy kidney tissue, addressing a critical gap in oncologic care. This work has helped establish SABR as a viable, organ-sparing alternative for patients with compromised kidneys, offering hope where few options existed. Waiser’s research is notable for its focus on patient-centered outcomes, balancing tumor control with renal function preservation, and has influenced clinical guidelines for managing RCC in complex cases. His contributions continue to shape the evolving landscape of noninvasive cancer therapy.

Research Focus

Key Achievements

1
H-Index
1
Papers
23
Total Citations
23
Avg Citations/Paper
🏆 Most Cited Paper
Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function
23 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Charité - Universitätsmedizin Berlin

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago